Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Kane, J. M. Articles by Karcher, K. Search for Related Content PubMed Citation Articles by Kane, J. M. Articles by Karcher, K. Schizophrenia Spectrum Disorders Atypical Neuroleptics

Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic

OBJECTIVE: The authors assessed the efficacy and safety of the first long-acting atypical antipsychotic (long-acting injectable risperidone) in patients with schizophrenia. METHOD: In a 12-week, multicenter, double-blind, randomized study, patients received intramuscular injections every 2 weeks of placebo or long-acting risperidone (25 mg, 50 mg, or 75 mg). The primary measure of efficacy was the change in total score on the Positive and Negative Syndrome Scale. RESULTS: Of the 554 patients who were enrolled, 400 entered the double-blind study, and 370 received at least one postbaseline assessment. Mean changes in score of –6.2, –8.5, and –7.4 on the Positive and Negative Syndrome Scale were seen at endpoint for the 25-, 50-, and 75-mg risperidone groups, respectively; all three change scores were significantly different from that seen with placebo (+2.6). Improvements in positive and negative symptoms were also significantly greater in patients receiving risperidone. Long-acting risperidone was well tolerated. Adverse events related to extrapyramidal symptoms were spontaneously reported by 13% of patients receiving placebo and 10% of patients in the 25-mg risperidone group, with higher rates in the 50-mg and 75-mg groups. Severity of extrapyramidal symptoms was mild at baseline and throughout the trial in each treatment group. Mean weight changes were small in the 25-, 50-, and 75-mg risperidone groups (0.5 kg, 1.2 kg, and 1.9 kg, respectively). Injection site pain was rated as low by the patients, consistent with the investigators’ pain ratings. CONCLUSIONS: Long-acting injectable risperidone was efficacious and well tolerated and provides both clinicians and patients with a new mode of treatment that can improve the outcome of long-term therapy.

This article has been cited by other articles:

				M. Taylor, A. Currie, K. Lloyd, M. Price, and K. Peperell Impact of risperidone long acting injection on resource utilization in psychiatric secondary care J Psychopharmacol, March 1, 2008; 22(2): 128 - 131. [Abstract] [PDF]

				J. Rabinowitz and O. Davidov The Association of Dropout and Outcome in Trials of Antipsychotic Medication and Its Implications for Dealing With Missing Data Schizophr Bull, March 1, 2008; 34(2): 286 - 291. [Abstract] [Full Text] [PDF]

				J. Rabinowitz, S. Z. Levine, O. Barkai, and O. Davidov Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features Schizophr Bull, February 26, 2008; (2008) sbn005v1. [Abstract] [Full Text] [PDF]

				J. Rabinowitz and O. Davidov A Composite Approach That Includes Dropout Rates When Analyzing Efficacy Data in Clinical Trials of Antipsychotic Medications Schizophr Bull, September 29, 2007; (2007) sbm107v1. [Abstract] [Full Text] [PDF]

				N. A. KEKS, M. INGHAM, A. KHAN, and K. KARCHER Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open-label study The British Journal of Psychiatry, August 1, 2007; 191(2): 131 - 139. [Abstract] [Full Text] [PDF]

				J. M. Noel ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders Am. J. Health Syst. Pharm., April 15, 2007; 64(8): 863 - 876. [Full Text] [PDF]

				S. Burton Symptom domains of schizophrenia: the role of atypical antipsychotic agents. J Psychopharmacol, November 1, 2006; 20(6 Suppl): 6 - 19. [Abstract] [PDF]

				P. Chue The relationship between patient satisfaction and treatment outcomes in schizophrenia. J Psychopharmacol, November 1, 2006; 20(6 Suppl): 38 - 56. [Abstract] [PDF]

				G. Remington, D. Mamo, A. Labelle, J. Reiss, C. Shammi, E. Mannaert, S. Mann, and S. Kapur A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone Am J Psychiatry, March 1, 2006; 163(3): 396 - 401. [Abstract] [Full Text] [PDF]

				L. B. Dunn, B. W. Palmer, M. Keehan, D. V. Jeste, and P. S. Appelbaum Assessment of Therapeutic Misconception in Older Schizophrenia Patients With a Brief Instrument Am J Psychiatry, March 1, 2006; 163(3): 500 - 506. [Abstract] [Full Text] [PDF]

				S. Dursun An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia J Psychopharmacol, September 1, 2005; 19(5_suppl): 3 - 4. [PDF]

				E. Parellada, R. Andrezina, V. Milanova, P. Glue, M. Masiak, M. St. J. Turner, R. Medori, and W. Gaebel Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable J Psychopharmacol, September 1, 2005; 19(5_suppl): 5 - 14. [Abstract] [PDF]

				W. Kissling, S. Heres, K. Lloyd, E. Sacchetti, P. Bouhours, R. Medori, and P. M. Llorca Direct transition to long-acting risperidone - analysis of long-term efficacy J Psychopharmacol, September 1, 2005; 19(5_suppl): 15 - 21. [Abstract] [PDF]

				A. Mohl, K. Westlye, S. Opjordsmoen, A. Lex, A. Schreiner, M. Benoit, P. Braunig, and R. Medori Long-acting risperidone in stable patients with schizoaffective disorder J Psychopharmacol, September 1, 2005; 19(5_suppl): 22 - 31. [Abstract] [PDF]

				M. Gastpar, M. Masiak, M. A. Latif, S. Frazzingaro, R. Medori, and E. -R. Lombertie Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine J Psychopharmacol, September 1, 2005; 19(5_suppl): 32 - 38. [Abstract] [PDF]

				M. X. Patel and A. S. David Why aren't depot antipsychotics prescribed more often and what can be done about it? Advan. Psychiatr. Treat., May 1, 2005; 11(3): 203 - 211. [Abstract] [Full Text] [PDF]

				M. J Ehret and M. A Fuller Long-Acting Injectable Risperidone Ann. Pharmacother., December 1, 2004; 38(12): 2122 - 2127. [Abstract] [Full Text] [PDF]

				S. J. Keith, L. Pani, B. Nick, R. Emsley, L. San, M. Turner, R. Conley, P. Scully, P. S. Chue, and B. Lachaux Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia Psychiatr Serv, September 1, 2004; 55(9): 997 - 1005. [Abstract] [Full Text] [PDF]

				M. D. Jibson, I. D. Glick, and R. Tandon Schizophrenia and Other Psychotic Disorders Focus, January 1, 2004; 2(1): 17 - 30. [Abstract] [Full Text] [PDF]

				C. Paton and C. Okocha Risperidone long-acting injection: the first 50 patients Psychiatr. Bull., January 1, 2004; 28(1): 12 - 14. [Abstract] [Full Text] [PDF]

				A Better Injectable Antipsychotic Medication? Journal Watch Psychiatry, August 6, 2003; 2003(806): 2 - 2. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us